Evidence map›Paper›PMID 23633287›Full record

ArticleJournal of neuroscience research2013

Estrogen receptor-β ligand treatment after disease onset is neuroprotective in the multiple sclerosis model.

Amy J Wisdom, Yuan Cao, Noriko Itoh, Rory D Spence, Rhonda R Voskuhl

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroscience research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol.Laboratory investigation; a journal of technical methods and pathology · 2023
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Systems Genetic Analysis in GeneNetwork.org.Current protocols in neuroscience · 2017
    Article
  8. Article
  9. Sex Drives Dimorphic Immune Responses to Viral Infections.Journal of immunology (Baltimore, Md. : 1950) · 2017
    Review
  10. Article
  11. Solving for (se)x.Lab animal · 2015
    Article
  12. Review
  13. PET imaging in multiple sclerosis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2014
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Amy J WisdomUCLA Multiple Sclerosis Program, Department of Neurology, University of California, Los Angeles, California 90095, USA.
Yuan Cao
Noriko Itoh
Rory D Spence
Rhonda R Voskuhl
University of California, Los Angeles · US

Funding

Stem CellsP30HD004612 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KORNBLUM, HARLEY IAN, SUN, YI EVE · 1985 to 2014
$19.5M
Neuroendocrinology, Sex Differences, and ReproductionT32HD007228 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARNOLD, ARTHUR P · 1985 to 2015
$3.9M
Protective Effect of Pregnancy Doses of Estrogens in EAER01NS045443 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSKUHL, RHONDA R · 2002 to 2005
$997k
Treatment of Multiple Sclerosis with Sex HormonesK24NS062117 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSKUHL, RHONDA R · 2008 to 2012
$722k
Howard Hughes Medical InstituteNICHD NIH HHS 5T32HD07228NICHD NIH HHS P30 HD004612NICHD NIH HHS T32 HD007228NINDS NIH HHS K24 NS062117NINDS NIH HHS R01 NS045443
6 · The paper itself

Abstract

Multiple sclerosis (MS) is an autoimmune disease characterized by inflammation and neurodegeneration. Current MS treatments were designed to reduce inflammation in MS rather than directly to prevent neurodegeneration. Estrogen has well-documented neuroprotective effects in a variety of disorders of the CNS, including experimental autoimmune encephalomyelitis (EAE), the most widely used mouse model of MS. Treatment with an estrogen receptor-β (ERβ) ligand is known to ameliorate clinical disease effectively and provide neuroprotection in EAE. However, the protective effects of this ERβ ligand have been demonstrated only when administered prior to disease (prophylactically). Here we tested whether ERβ ligand treatment could provide clinical protection when treatment was initiated after onset of disease (therapeutically). We found that therapeutic treatment effectively ameliorated clinical disease in EAE. Specifically, ERβ ligand-treated animals exhibited preserved axons and myelin compared with vehicle-treated animals. We observed no difference in the number of T lymphocytes, macrophages, or microglia in the CNS of vehicle- vs. ERβ ligand-treated animals. Our findings show that therapeutically administered ERβ ligand successfully treats clinical EAE, bearing translational relevance to MS as a candidate neuroprotective agent.

Indexed as

AnimalsAxonsDemyelinating DiseasesDisease Models, AnimalEncephalomyelitis, Autoimmune, ExperimentalFemaleFreund's AdjuvantMiceMice, Inbred C57BLMyelin-Oligodendrocyte GlycoproteinNeuroprotective AgentsNitrilesPeptide FragmentsPropionatesReceptors, EstrogenSeverity of Illness Index2,3-bis(4-hydroxyphenyl)-propionitrileFreund's AdjuvantMyelin-Oligodendrocyte Glycoproteinmyelin oligodendrocyte glycoprotein (35-55)Neuroprotective AgentsNitrilesPeptide FragmentsPropionatesReceptors, Estrogen

Identifiers

PMID23633287
PMCPMC4376676
OpenAlexW1773473219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.